Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | 0.00% | -4.02% | +4.38% |
May. 16 | Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing | MT |
May. 13 | Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 55.48M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -23M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.55
x | P/E ratio 2025 * |
-2.41
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.86% |
1 week | -4.02% | ||
Current month | +0.60% | ||
1 month | -4.02% | ||
3 months | +2.45% | ||
6 months | -76.97% | ||
Current year | +4.38% |
Managers | Title | Age | Since |
---|---|---|---|
Niall O'Donnell
FOU | Founder | 51 | - |
Gregory Flesher
CEO | Chief Executive Officer | 54 | 20-12-08 |
Michael Grey
FOU | Founder | 71 | 14-09-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Grey
FOU | Founder | 71 | 14-09-21 |
Director/Board Member | 64 | 17-11-30 | |
Paul Hoelscher
BRD | Director/Board Member | 59 | 22-01-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.49% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +3.46% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 1.66 | -0.60% | 47,622 |
24-06-03 | 1.67 | +0.60% | 38,485 |
24-05-31 | 1.66 | -3.49% | 108,667 |
24-05-30 | 1.72 | +1.78% | 50,715 |
24-05-29 | 1.69 | -2.87% | 83,705 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.38% | 55.48M | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+40.06% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- RPHM Stock